Mode
Text Size
Log in / Sign up
Phase 3 Completed N=1,509 Randomized Quadruple-blind Treatment

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Prostate Cancer Non-Metastatic · Castration-Resistant
Source: ClinicalTrials.gov NCT02200614 ↗
Enrolled (actual)
1,509
Serious AEs
29.7%
Results posted
Oct 2019
Primary outcomePrimary: Metastasis-Free Survival — 40.37; 18.43 months — p=<0.000001
◆ Published Evidence
Emerging
16citations · ~5 / year
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
European journal of cancer (Oxford, England : 1990) · 2023 · Open access · Likely link

Summary

The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.

Linked Publications (5)

  • Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
    European journal of cancer (Oxford, England : 1990) · 2023 · 16 citations · Open access · Likely link
  • Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
    The oncologist · 2024 · 7 citations · Open access · Likely link
  • Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
    Future oncology (London, England) · 2023 · 4 citations · Open access · Likely link
  • Lower Testosterone Level and Metastases-Free Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With Novel Antiandrogens: A Post Hoc Analysis of SPARTAN and ARAMIS.
    The Journal of urology · 2025 · 1 citation · Likely link
  • Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS.
    Cancer medicine · 2026 · 0 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Metastasis-Free Survival
40.37; 18.43 <0.000001 sig
SECONDARY
Overall Survival - Primary Analysis
NA; NA 0.045210 sig
SECONDARY
Time to Pain Progression - Primary Analysis
40.31; 25.36 0.000008 sig
SECONDARY
Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Primary Analysis
NA; 38.21 <0.000001 sig
SECONDARY
Time to First Symptomatic Skeletal Event (SSE) - Primary Analysis
NA; NA 0.011262 sig
SECONDARY
Overall Survival - Final Analysis
NA; NA 0.003048 sig
SECONDARY
Time to Pain Progression - Final Analysis
40.31; 25.36 0.000008 sig
SECONDARY
Time to Initiation of First Cytotoxic Chemotherapy for Prostate Cancer - Final Analysis
NA; NA 0.000044 sig
SECONDARY
Time to First Symptomatic Skeletal Event (SSE) - Final Analysis
NA; NA 0.005294 sig

Eligibility Criteria

Inclusion Criteria

  • Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.
  • Castration-resistant prostate cancer (CRPC) with castrate level of serum testosterone.
  • Prostate-specific Antigen (PSA) doubling time of ≤ 10 months and PSA > 2ng/ml.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Blood counts at screening: haemoglobin ≥ 9.0 g/dl,absolute neutrophil count ≥ 1500/µl, platelet count ≥ 100,000/µl.
  • Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase (AST) ≤ 2.5 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN, creatinine ≤ 2.0 x ULN.
  • Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method and refrain from sperm donation during the study treatment and for 3 months after the end of the study treatment.

Exclusion Criteria

  • History of metastatic disease at any time or presence of detectable metastases.
  • Acute toxicities of prior treatments and procedures not resolved to grade ≤ 1 or baseline before randomisation.
  • Prior treatment with: second generation androgen receptor (AR) inhibitors, other investigational AR inhibitors, or CYP17 enzyme inhibitor.
  • Use of estrogens or 5-α reductase inhibitors or AR inhibitors.
  • Prior chemotherapy or immunotherapy for prostate cancer.
  • Use of systemic corticosteroid.
  • Radiation therapy within 12 weeks before randomisation.
  • Severe or uncontrolled concurrent disease, infection or co-morbidity.
  • Treatment with bisphosphonate or denosumab within 12 weeks before randomisation.
  • Known hypersensitivity to the study treatment or any of its ingredients.
  • Major surgery within 28 days before randomisation.
  • Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV.
  • Uncontrolled hypertension.
  • Prior malignancy.
  • Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.
  • Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.
  • Treatment with any investigational drug within 28 days before randomisation.
  • Any condition that in the opinion of the investigator would impair the patients' ability to comply with the study procedures.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02200614) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search